Details of the Drug

General Information of Drug (ID: DMHM93Y)

• Drug Name: Meprobamate
• Synonyms: meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas; Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1], [2]
Malaria	1F40-1F45	Approved	[3], [4]
Ischemic reperfusion injury	DB98.B	Discontinued in Phase 1	[5]

• Therapeutic Class: Antianxiety Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 218.25
  Topological Polar Surface Area (xlogp); 0.7
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption: The drug is well absorbed from the gastrointestinal tract [6]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [7]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.6 mL/min/kg [8]
  Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours [8]
  Metabolism: The drug is metabolized via the hepatic [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 157.0936 micromolar/kg/day [9]
  Unbound Fraction: The unbound fraction of drug in plasma is 1% [8]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.7 L/kg [8]
  Water Solubility: The ability of drug to dissolve in water is measured as 3.4 mg/mL [7]
• Chemical Identifiers:
  Formula: C9H18N2O4
  IUPAC Name: [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
  Canonical SMILES: CCCC(C)(COC(=O)N)COC(=O)N
  InChI: InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
  InChIKey: NPPQSCRMBWNHMW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4064
  ChEBI ID: CHEBI:6761
  CAS Number: 57-53-4
  DrugBank ID: DB00371
  TTD ID: D0Y4AW
  INTEDE ID: DR1029
  ACDINA ID: D00398

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Antagonist	[10]
Polypeptide deformylase (PDF)	TT9SL3Q	DEFM_HUMAN	Inhibitor	[3]
Protein kinase C epsilon (PRKCE)	TTBZ7OD	KPCE_HUMAN	Stimulator	[11]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[13]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Meprobamate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Meprobamate and Oliceridine.	Acute pain [MG31]	[63]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Meprobamate and Dihydrocodeine.	Chronic pain [MG30]	[64]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Meprobamate and Olopatadine.	Conjunctiva disorder [9A60]	[65]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Meprobamate and Propofol.	Corneal disease [9A76-9A78]	[66]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Meprobamate and Alfentanil.	Corneal disease [9A76-9A78]	[63]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Meprobamate and Remifentanil.	Corneal disease [9A76-9A78]	[63]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Meprobamate and Esketamine.	Depression [6A70-6A7Z]	[67]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Meprobamate and Brimonidine.	Glaucoma [9C61]	[68]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Meprobamate and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[69]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Meprobamate and Lasmiditan.	Migraine [8A80]	[70]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Meprobamate and Flibanserin.	Mood disorder [6A60-6E23]	[71]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Meprobamate and Thalidomide.	Multiple myeloma [2A83]	[72]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Meprobamate and Levomethadyl Acetate.	Opioid use disorder [6C43]	[64]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Meprobamate and Apraclonidine.	Optic nerve disorder [9C40]	[68]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Meprobamate and Dextropropoxyphene.	Pain [MG30-MG3Z]	[73]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Meprobamate and Butorphanol.	Pain [MG30-MG3Z]	[63]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Meprobamate and Oxymorphone.	Pain [MG30-MG3Z]	[63]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Meprobamate and Levorphanol.	Pain [MG30-MG3Z]	[63]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Meprobamate and Dezocine.	Pain [MG30-MG3Z]	[63]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Meprobamate and Nalbuphine.	Pain [MG30-MG3Z]	[63]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Meprobamate and Buprenorphine.	Pain [MG30-MG3Z]	[74]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Meprobamate and Hydrocodone.	Pain [MG30-MG3Z]	[63]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Meprobamate and Meperidine.	Pain [MG30-MG3Z]	[63]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Meprobamate and Oxycodone.	Pain [MG30-MG3Z]	[63]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Meprobamate and Fentanyl.	Sensation disturbance [MB40]	[63]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Meprobamate and Sufentanil.	Sensation disturbance [MB40]	[63]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Meprobamate 200 mg tablet	200 mg	Oral Tablet	Oral
Meprobamate 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7225).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040797.
• [3] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026294)
• [6] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [7] BDDCS applied to over 900 drugs
• [8] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [9] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [10] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [11] Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
• [12] Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther. 2002 Jan;300(1):273-81.
• [13] Solid-phase synthesis of drug glucuronides by immobilized glucuronosyltransferase. J Med Chem. 1976 May;19(5):679-83.
• [14] Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
• [15] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [16] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [17] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [18] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [19] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [20] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [21] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [22] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [23] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [24] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [25] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [26] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [27] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [28] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [29] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [30] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [31] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [32] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [33] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [34] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [35] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [36] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [37] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [38] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [39] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [40] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [41] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [42] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [43] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [44] Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
• [45] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [46] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [47] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002)
• [48] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [49] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [50] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [51] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [52] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [53] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [54] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [55] Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
• [56] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [57] Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
• [58] Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
• [59] Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
• [60] Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
• [61] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [62] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [63] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [64] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [65] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [66] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [67] Cerner Multum, Inc. "Australian Product Information.".
• [68] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [69] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [70] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [71] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [72] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [73] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [74] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]